| Clinical data | |
|---|---|
| Trade names | Eminase |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Half-life | 90 minutes |
| Identifiers | |
| CAS number | 81669-57-0 |
| ATC code | B01AD03 |
| DrugBank | BTD00102 |
| KEGG | D02947 |
| Chemical data | |
| Formula | ? |
| Mol. mass | approx. 131,000 g/mol |
| (what is this?) (verify) |
|
Anistreplase is a thrombolytic drug.[1][2][3]
Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC)
It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||